Skip to main content
Download PDF

Small heterodimer partner interacting leucine zipper protein (SMILE) ameliorates autoimmune arthritis via AMPK signaling pathway and the regulation of B cell activation

Cell Communication and Signaling volume 21, Article number: 98 (2023) Cite this article

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease that causes joint swelling and inflammation and can involve the entire body. RA is characterized by the increase of pro-inflammatory cytokines such as interleukin (IL) and tumor necrosis factor, and the over-activation of T lymphocytes and B lymphocytes, which may lead to severe chronic inflammation of joints. However, despite numerous studies the pathogenesis and treatment of RA remain unresolved. This study investigated the use of small heterodimer partner-interacting leucine zipper protein (SMILE) overexpression to treat a mouse model of RA. SMILE is an insulin-inducible corepressor through adenosine monophosphate-activated kinase (AMPK) signaling pathway. The injection of a SMILE overexpression vector to mice with collagen induced-arthritis resulted in a milder clinical pathology and a reduced incidence of arthritis, less joint tissue damage, and lower levels of Th17 cells and plasma B cells in the spleen. Immunohistochemistry of the joint tissue showed that SMILE decreased B-cell activating factor (BAFF) receptor (BAFF-R), mTOR, and STAT3 expression but increased AMPK expression. In SMILE-overexpressing transgenic mice with collagen antibody-induced arthritis (CAIA), a decrease in the arthritis score and reductions in tissue damage, the number of B cells, and antibody production were observed. The treatment of immune cells in vitro with curcumin, a known SMILE-inducing agent, led to decreases in plasma B cells, germinal center B cells, IL-17-producing B cells, and BAFF-R-positive B cells. Taken together, our findings demonstrate the therapeutic potential of SMILE in RA, based on its inhibition of B cell activation mediated by the AMPK/mTOR and STAT3 signaling pathway and BAFF-R expression.

Video abstract

Introduction

Small heterodimer partner-interacting leucine zipper protein (SMILE) is an isoform of the transcription factor cyclic AMP-response element binding protein Zhangfei (CREBZF) [1]. CREBZF is a member of the activating transcription factor/cAMP response element binding protein (ATF/CREB) family that regulates various cellular functions, including transcription [2,3,4]. SMILE is an insulin-inducible corepressor that acts by decreasing PGC-1α expression [5], hepatic glucogenesis [6], and adenosine monophosphate-activated kinase (AMPK) signaling [7]. Despite its many roles in cells, the underlying mechanism and role of SMILE in immune cells are unknown. In this study, a mouse model of rheumatoid arthritis (RA) was used to investigate the effect of SMILE expression on immune cells.

RA is a systemic chronic autoimmune disease characterized by synovitis, increases in pro-inflammatory cytokines such as interleukins (ILs) and tumor necrosis factor (TNF), and the overactivation of T and B lymphocytes [8, 9]. Although RA does not significantly affect survival, it causes chronic pain following the erosion and destruction of cartilage, bone, and tendons [10]. The pathogenesis of RA is complex and no single drug is effective in its treatment completely; many patients are unresponsive, including to methotrexate [11]. Accordingly, more effective control for RA is needed.

Many previous studies of RA have focused on the role of T lymphocytes [12,13,14]. Activated T helper (Th)1, Th17, and autoreactive CD4+ T cells have been implicated in the pathogenesis of RA together with pro-inflammatory cytokines secreted by T cells, including IL-6, IL-17, IL-23, and TNF [15,16,17,18]. However, B cells play an equally important role in RA, as their accumulation in tertiary lymphoid tissues (TLTs) is related to higher RA pathogenic scores and T cell activation in RA patients [19,20,21]. Among the chemokines and inflammatory factors expressed by TLTs are LTα, LTβ, CXCL13, CCL20, CCL21, and CXCL12, all of which induce inflammation and the infiltration of inflammatory cells into joints [22,23,24,25]. The production of autoantibodies by B cells also contributes to the pathogenesis of RA [21, 26, 27]. For example, anti-citrullinated protein antibodies are commonly detected in patients with RA and are the focus of current interest in approaches based on targeted therapy [28].

This study investigated the potential therapeutic effect of SMILE expression in a mouse model of RA. Mice with collagen-induced arthritis (CIA) were injected with a SMILE overexpression vector and SMILE overexpression transgenic mice were used for collagen antibody-induced arthritis (CAIA). Besides, the effect of curcumin (diferuloylmethane) in CIA mice was determined as well, as a previous study showed that it induces SMILE expression via AMPK signaling and the suppression of endoplasmic reticulum stress-responsive gene transcription. Therefore, we treated curcumin with splenocytes and analyzed the proportion of immune cells.

Our results showed that SMILE expression inhibits B cell activation and differentiation in mouse models of RA, thus demonstrating its potential efficacy as a therapeutic regulator in autoimmune diseases such as RA.

Materials & methods

Animals

Seven-week-old male DBA/1 J mice (Orient Bio, Gyeonggi-do, Korea) were purchased from Orient Bio Inc. (South Korea). The animals were maintained under specific pathogen-free conditions in an animal facility with controlled humidity (55 ± 5%), light (12 h/12 h light/dark), and temperature (22 ± 1 °C). The air in the facility passed through a HEPA filter system designed to exclude bacteria and viruses. Animals were fed mice chow and water ad libitum. All experimental procedures were provided in accordance with the Laboratory Animals Welfare Act, the Guide for the Care and Use of Laboratory Animals and the Guidelines and Policies for Rodent experiment provided by the IACUC (Institutional Animal Care and Use Committee) in school of medicine, The Catholic University of Korea. To generate SMILE transgenic mice, a pcDNA3.0 vector was constructed containing a cytomegalovirus promoter. The SMILE fragment was synthesized by GenScript Corporation (USA), with codon optimization for expression in mammalian cells. The open reading frame originated in mice. Transgenic mice overexpressing SMILE were generated on a C57BL/6 background by transgene microinjection and maintained at Macrogen Inc. (South Korea). SMILE transgenic founder mice were mated to C57BL/6 mice and were crossed for 10 generations. The presence of the transgene in the founders was confirmed by polymerase chain reaction (PCR) using genomic DNA extracted from the tail. All experimental procedures were evaluated and conducted in accordance with the protocols approved by the Animal Research Ethics Committee at the Catholic University of Korea (Permit Number: 2021-0010-01, 2020-0306-02).

Induction and assessment of collagen induced arthritis (CIA) and SMILE administration

To induce CIA, 0.1 mL of emulsion containing 100 μg of bovine type II collagen (CII) and Freund’s complete adjuvant (Chondrex, WA, USA) and Freund’s complete adjuvant (Chondrex) was injected intradermal into the base of the tail as a primary immunization. Two weeks later, a booster injection of 100 μg CII dissolved and emulsified 1:1 with water, a booster Freund’s incomplete adjuvant (Difco, MI, USA) was administered into the tail. At 1 week after collagen-induced arthritis (CIA) induction, SMILE mock control vector was administered by electroporation; weekly hydrodynamic injection was then performed for 10 weeks, as described previously. SMILE overexpression experiments, SMILE cDNA fragment was cloned into the pcDNA3.0 vector between EcoRI and KpnI. Escherichia coli containing the SMILE overexpression vector were incubated in Luria–Bertani high salt broth (Duchefa Biochemie, Netherlands) for 16 h at 37 °C and 160 rpm. The cells were harvested by centrifugation, the SMILE overexpression vector purified using a NucleoBond Xtra Maxi EF Kit (Macherey–Nagel, Germany). Mice were intravenously injected with 100 μg of SMILE overexpression vector or control vector in 1 mL of saline.

Induction and assessment of collagen antibody-induced arthritis (CAIA)

Eight-week-old male C57BL/6 mice and SMILE transgenic mice were used for the induction of CAIA. Anti-collagen antibodies 2 mg (Chondrex) were injected intravenously in to 2 groups of mice, and 3 days later, 50 μg of LPS was administered intraperitoneally. Mice were monitored and evaluated daily for arthritis.

Clinical assessment of arthritis

The severity of arthritis was evaluated by three independent observers. The mice were observed twice weekly or daily to determine the onset and severity of joint inflammation for up to 7 weeks after the primary immunization. The severity of arthritis was assessed on a scale of 0–4, based on the following criteria: 0 = no edema or swelling 1 = slight edema, with erythema with erythema limited to the foot or ankle; 2 = slight edema, with erythema from the ankle to the tarsal bone; 3 = moderate edema, with erythema from the ankle to the tarsal bone; and 4 = severe edema, with erythema from the ankle to the entire leg. The arthritis score of each mouse was calculated as the sum of the scores of the four limbs; the highest possible arthritis score for each mouse was 16. The mean arthritis index was used to compare the scores of the control and experimental groups [29].

Histological analysis

Mouse joint tissues were fixed in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA), decalcified in a histological decalcifying solution (Calci-Clear Rapid; National Diagnostics, Atlanta, GA, USA), and embedded in paraffin wax for histological analyses. Sections (7 mm) were prepared and stained with hematoxylin (YD Diagnostics, Yongin, Korea), eosin (Muto Pure Chemicals Co., Ltd., Tokyo, Japan), and safranin O (Sigma-Aldrich) [30].

Immunohistopathological analysis of arthritis

Joint tissues were incubated overnight at 4 °C with primary antibodies against SMILE (Abcam, Cambridge, UK), B-cell activating factor receptor (BAFF-R) (Abcam), pAMPK (Abcam), mTOR (Cell Signaling, MA, USA), pSTAT3 ser727 (Abcam), Pstat3 Tyr705 (Abcam), IL-1β (Abcam), IL-6 (Abcam), IL-17(Abcam). Subsequently, samples were incubated with a biotinylated streptavidin–peroxidase complex for 1 h, and the signals were developed using chromogen 3,3′- diaminobenzidine (Thermo Scientific, Rockford, IL, USA). The sections were examined under a photomicroscope (Olympus, Tokyo, Japan). The number of positive cells in high-power digital images (magnification, ×400) was counted using Adobe Photoshop software (Adobe, San Jose, CA, USA). Stained cells were counted independently by three observers, and the mean values were evaluated.

Immunofluorescence imaging

Th17 (CD4, IL-17), Treg (CD4, CD25, Foxp3), SMILE, AMPK, mTOR, pSTAT3 705, pSTAT3 727 and germinal center markers (CD3, B220, PNA) expression levels were analyzed by confocal microscopy. Tissue Sects. (7 μm thick) were fixed in methanol-acetone and stained with phycoerythrin (PE)-conjugated anti-CD4 (Biolegend, San Diego, CA, USA), fluorescein isothiocyanate (FITC)-conjugated anti CD4 (BD Bioscience, San Diego, CA, USA), PE-conjugated anti-interleukin-17 (eBioscience, San Diego, CA, USA), allophycocyanin (APC)-conjugated anti-CD25 (Biolegend), PE-conjugated anti-Foxp3 (Thermo Fisher Scientific, Waltham, MA, USA), PE-conjugated anti-phosphorylated Stat3 (Tyr 705, Ser 727, BD Bioscience), APC-conjugated anti-B220 (eBioscience), Alexa 594-conjugated anti-PNA (Thermo Fisher Scientific), SMILE (Abcam, Cambridge, UK), AMPK (Abcam) and mTOR (Cell Signaling). After overnight incubation at 4℃, the stained sections were analyzed on a Zeiss confocal microscope (LSM 700; Carl Zeiss, Oberkochen, Germany) at 200× magnification and Zen Blue edition software.

Western blotting

Cells were lysed in RIPA lysis and extraction buffer containing Halt protease inhibitor cocktail (Thermo Scientific, USA). Lysates were centrifuged at 14,000 rpm for 15 min at 4 °C. Protein concentration was determined using a Pierce BCA Protein Assay Kit (Thermo Scientific, USA). Proteins were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to membranes (GE Healthcare, USA). The membranes were incubated with antibodies against SMILE, phosphorylated AMPK (Cell Signaling, MA, USA), SMILE, GAPDH (Abcam, Cambridge, UK). Hybridized bands were detected by enhanced chemiluminescence (Thermo Scientific, USA) on X-ray film (AGFA, Belgium). Western blotting was performed using the SNAP i.e. Protein Detection System.

Isolation and stimulation of splenocytes and culture

Splenocytes were prepared from the spleens of Collagen induced arthritis mice. Splenocytes were maintained in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 5% fetal bovine serum (Gibco, Grand Island, NY, USA). Splenocytes were stimulated with or Curcumin (Sigma-Aldrich) 25 μg and LPS (Sigma-Aldrich) 100 ng/mL for 12 h and 72 h; they were then subjected to western blot analysis and flow cytometry, respectively.

Flow cytometry

The spleens were removed from the mice and single cells were isolated and stained using fluorescently conjugated antibodies against Follicular B and Marginal B cells; APC-conjugated anti-B220 (eBioscience), Percp/Cy5.5-conjugated CD23 (Biolegned) and Pacific Blue-conjugated CD21 (Biolegend), Mature B and Immature B cells; APC-conjugated anti-B220 (eBioscience), FITC-conjugated anti IgD (Thermo Fisher Scientific) and PE-conjugated anti-IgM (Thermo Fisher Scientific), regulatory B cells; FITC-conjugated anti-CD5 (Invitrogen), PE-conjugated CD1d (eBioscience) and PE/Cy7-conjugated anti-CD19 (BD Bioscience), Plasma B; ACP-conjugated anti-B220 (eBioscience) and PE-conjugated anti-CD 138 (BD Bioscience), Germinal center B; APC-conjugated anti-B220 (eBioscience) and Alexa Flour 488-conjugated anti-GL7 (Biolegend), IL-17 secreting B; PE/Cy7-conjugated anti-CD19 (BD Bioscience) and PE-conjugated anti-interleukin-17 (eBioscience) and BAFF-R; PE/Cy7-conjugated anti-CD19 (BD Bioscience) and PE-conjugated anti-CD268 (Biolegend). Prior to intracellular staining, cells were stimulated for 4 h with phorbol 12-myristate 13-acetate (PMA) (25 ng/mL) and ionomycin (250 ng/mL) in the presence of GolgiStop™ (BD Biosciences, USA). Intracellular staining was performed using a BD Cytofix/Cytoperm Plus Fixation/Permeabilization Kit and BD Golgistop Kit (BD Biosciences, USA). The transcription factor Foxp3 was stained using a Foxp3/Transcription Factor Staining Kit (eBioscience, USA) according to the manufacturer’s instructions. Flow cytometry was performed using a cytoFLEX Flow Cytometer (Beckman Coulter, USA).

Measurement of immunoglobulin

Serum was gathered when sacrificed for concentration of Total IgG, IgG1 and IgG2a, and the serum was stored at – 70 °C until further use. The levels of the Total IgG, IgG1 and IgG2a antibodies in the serum were measured using ELISA (Bethyl Laboratories, Montgomery, TX, USA).

Statistical analysis

Statistical analysis was performed using Prism9 (GraphPad Software, USA). Normally distributed continuous data were analyzed by parametric Student’s t-test. Differences in means among groups were subjected to analysis of variance followed by Bonferroni post hoc test. Values are means ± standard error of the mean (SEM). A value of P < 0.05 was indicative of statistical significance.

Results

SMILE overexpression inhibits RA pathogenesis in a CIA mouse model

The SMILE mRNA levels in peripheral blood mononuclear cells (PBMCs) from healthy controls and RA patients were examined using information contained in the National Center for Biotechnology Information Gene Expression Omnibus database. In our analysis, SMILE expression was significantly lower in RA patients than in healthy controls (Fig. 1A), suggesting a positive effect of SMILE in alleviating the symptoms of RA. We therefore investigated the effect of SMILE overexpression in a mouse model of RA. In RA mice injected with a SMILE overexpression vector (SMILE OV), SMILE and phosphorylated AMPK (p-AMPK) levels were significantly increased compared to the levels in control mice (Mock) (Fig. 1B and C). Measurements of the arthritis score and incidence in SMILE OV mice and Mock mice for 11 weeks showed that both values were significantly decreased in the SMILE mice (Fig. 1D). In hematoxylin and eosin (H&E)- and safranin O-stained joint tissue sections, The histological score, bone erosion score and cartilage damage score of SMILE OV were significantly decreased (Fig. 1E). In addition, IgG1 levels of serum were reduced by the overexpression of SMILE (Fig. 1F). This result showed that the SMILE overexpression vector was seen to have a protective effect on joint damage in RA mice.

Fig. 1
figure 1

SMILE overexpression attenuates RA pathogenesis in Collagen Induced Arthritis (CIA) mouse model. A The expression of SMILE which is coded by Crebzf in PBMCs from RA patients and healthy controls. B, C Lysates of NIH3T3 cells transfected with a mock vector or the SMILE vector were analyzed for SMILE and phosphorylated AMPK (p-AMPK) expression using western blotting. D CIA was induced in DBA1/J mice. On days 7 and 21 post immunization, mock or SMILE overexpression vectors were hydro dynamically injected. Vectors were also administered in the thigh area and transfected via electroporation once every 10 days until the end of the experiment. Arthritis scores were determined at different time points during the experimental period. E Tissue sections of the joints of mice treated with mock vector or the SMILE vector were immunostained with H&E (bar = 100 µm) and safranin O (bar = 100 µm), and the histologic score for features of arthritis were determined. The dots of bar graph represent 1 mouse respectively. F Concentrations of type II collagen (CII)-specific total IgG and IgG2a as determined by enzyme-linked immunosorbent assays. The results are the mean ± SD of three independent experiments. Data are presented as the *P < 0.05 and **P < 0.01

Full size image

Modification of the BAFF receptor (BAFF-R), p-AMPK, mTOR, and STAT3 expression in SMILE mice

To identify the signaling pathway by which SMILE expression suppresses RA symptoms, the joint tissues of RA mice were examined by immunohistochemistry. In SMILE OV mice, SMILE expression was elevated and the expression of BAFF-R in joint tissue was significantly reduced (Fig. 2A). Several signaling pathways (p-AMPK, mTOR, and STAT3) related to the production of pro-inflammatory cytokines were investigated as well, which showed the increased expression of p-AMPK and decreased expression of mTOR and STAT3 in SMILE OV mice compared to Mock mice (Fig. 2B). This result suggested that SMILE protein expression can ameliorate RA symptoms by reducing BAFF-R and regulating the levels of immune cells and thus of cytokines via the AMPK/mTOR signaling and STAT3 pathways.

Fig. 2
figure 2

SMILE decreases BAFF-R, p-AMPK, mTOR, and STAT3 expression in CIA mice. Immunohistochemical staining of the joints of DBA1/J mice with CIA injected or not with the SMILE vector. A Tissue sections of mouse joints immunohistochemically stained for SMILE and BAFF-R. B Staining for anti-pAMPK, mTOR, pSTAT3 (ser727), and pSTAT3 (Thy705). Bars show the percentages of positive areas per field. Every dots represent 1 mouse respectively

Full size image

SMILE expression regulates the immune cell population

The ability of SMILE to regulate immune cells was examined by immunofluorescence staining of mouse spleen tissue. The results showed that SMILE overexpression decreased the number of Th17 cells (CD4+ IL-17+ cells) and increased the number of regulatory T cells (Treg; CD4+ CD25+ Foxp3+ cells) (Fig. 3A). Although not significant, there were also changes in the populations of regulatory B (Breg; CD5+ CD1Dhigh CD19+) cells, follicular B (FoB; CD23+ CD21low B220+) cells, marginal zone B (MZB; CD23low CD21+ B220+) cells, mature B (IgDhigh IgMlow B220+) cells, and immature B (IgDlow IgMhigh B220+) cells (Fig. 3B). These data were consistent with the regulation of immune cell populations by SMILE.

Fig. 3
figure 3

SMILE regulates the proportions of Th17 and Treg cells in CIA mice treated with the SMILE vector. A Immunofluorescence data of spleen cryosections from CIA mice administered a mock or SMILE vector using confocal microscopy. The sections were stained for CD4 and IL-17 (Th17 cells) or CD4, CD25, and Foxp3 (Treg cells) (original magnification, 200×). B Flow cytometry data of FoB cells (CD23+CD21low in B220 cells), MZB cells (CD23lowCD21+ in B220 cells), mature B cells (IgDhigh IgMlow in B220 cells), immature B cells (IgDlow IgMhigh in B220 cells), and B regulatory cells (CD5+CD1dhigh in CD19 cells) in CIA mice administered a mock or SMILE vector. Every dots represent 1 mouse respectively

Full size image

Anti-inflammatory effect on CAIA in SMILE-overexpressing transgenic mice

To investigate whether the effect of vector-mediated SMILE upregulation persisted, transgenic mice overexpressing SMILE (SMILE Tg) were established based on C57BL/6. Control (C57BL/6) and SMILE Tg mice were induced with CAIA. The arthritis scores and incidences of the SMILE Tg mice were lower than those of control mice (Fig. 4A). H&E and safranin O staining showed less histological damage, bone erosion and cartilage damage in SMILE Tg mice than in control C57BL/6 mice (Fig. 4B), as well as decreases in the total IgG and IgG2a levels (Fig. 4C). Immunohistochemistry of pro-inflammatory cytokine expression in mouse joint tissues showed that the IL-1β, IL-6, and IL-17 levels were significantly decreased in SMILE Tg mice (Fig. 4D), thus demonstrating the anti-inflammatory effect of SMILE on arthritis in SMILE Tg mice.

Fig. 4
figure 4

Attenuation of RA pathology in Collagen Antibody-Induced Arthritis (CAIA) SMILE transgenic (SMILE Tg) mice. CAIA was induced in wild-type (WT) C57BL/6 mice and SMILE Tg mice. A The severity of symptoms in each paw was scored daily on a scale from 0 (no symptoms) to 4 (maximal level of symptoms) and the scores for four limbs were summed. B Ten days after CAIA induction, tissue sections form the paw and ankle joints of the mice were stained with H&E. Representative histological features are shown. The quantified levels of inflammation, bone damage, and cartilage damage are shown in the graphs. C The levels of total IgG and IgG2a antibodies in the serum of CAIA mice 10 days after the first immunization. D Representative immunohistochemistry images showing that SMILE overexpression alleviated RA in CAIA mice. SMILE overexpression inhibited the expressions of IL-1β, IL-6, and IL-17 in CAIA mouse joints. Synovial sections from C57BL/6 and SMILE Tg mice stained for IL-1β, IL-6, and IL-17. Scale bar = 100 µm. *P < 0.05 and **P < 0.01. Every dots represent 1 mouse respectively

Full size image

SMILE-mediated inhibition of plasma B cell development and germinal center (GC) B cells

Immunofluorescence was performed on mouse spleen tissue to identify the cells and pathways modified in SMILE Tg mice. First, the significantly increased expression of SMILE in SMILE Tg mice was confirmed. It was then shown that while AMPK expression was increased in SMILE Tg mice, mTOR expression was notably decreased in the SMILE Tg mice (Fig. 5A). Although CD3, a T cell marker, has no significant difference between C57BL/6 mice and SMILE Tg mice, the significantly reduced expression of B220, a B cell marker, and PNA, a germinal center (GC) B cell marker, was also found in the spleens of SMILE Tg mice (Fig. 5B). Also, the phosphorylated STAT3 (p-STAT3) expression was decreased in SMILE Tg mice (Fig. 5C). These results showed that SMILE inhibits the development of B cells by decreasing the activities of the AMPK/mTOR and STAT3 signaling pathways, thereby suppressing the progression of arthritis.

Fig. 5
figure 5

Effect of SMILE on germinal center (GC) B cell formation and signaling pathway in the spleen tissue of SMILE Tg mice. A The median fluorescence intensity (MFI) of SMILE, AMPK, and mTOR in CAIA C57BL/6 mice spleen and SMILE Tg mice spleen respectively. B B220+PNA+ GC B cells was analyzed by immunofluorescence. There was no significant difference in CD3, however, the expression of B220 and PNA was significantly decreased in SMILE Tg. C The phosphorylated (pSTAT3) 727 and pSTAT3 705 expression were decreased in SMILE Tg mice. Original magnification in 200×

Full size image

Curcumin inhibits the activation of B cells

As a previous study showed that curcumin increases the expression of SMILE, in this study curcumin was used as an inducer of SMILE [31,32,33]. The CIA mice splenocytes were cultured in the presence of 100 ng/mL of lipopolysaccharide (LPS) and treated with 50 μM curcumin. The results showed significant increases in the translation of SMILE (Fig. 6A). Curcumin treatment in the presence of 100 ng/mL of LPS reduced the population of CD19+ B cells and B220+ B cells expressing BAFF-R. However, in the group treated with the Compound C which is an AMPK inhibitor, the populations of CD19+ B cells and B220+ B cells expressing BAFF-R did not change. (Fig. 6B). BAFF-R-positive B (CD19+ BAFF-R+) cells, IL-17 secreting B (CD19+ IL-17+) cells, Plasma B (B220− CD138+) cells and GC B (B220+ GL7+) cells proportion were decreased by curcumin treatment (Fig. 6C). This result showed that a curcumin-mediated increase in SMILE expression inhibits the development of B cells and suppresses the expression of BAFF-R in CD19+ B cells and CD220+ B cells through regulation of AMPK signaling pathway.

Fig. 6
figure 6

Effect of curcumin treatment on mice splenocytes in vitro. CIA mice splenocytes were stimulated with LPS in the presence of curcumin and/or compound C for 3 days and then analyzed by flow cytometry. A Western blots of SMILE expression in the splenocytes of curcumin (25 μM)-treated mice administered LPS (100 ng/mL) and untreated mice after 6 h. The SMILE expression was elevated in curcumin treated cells. B Expression of BAFF-R- and CD19-positive cells. Both cells were decreased by curcumin treatment, but curcumin had no effect in the group treated with the AMPK inhibitor compound C. C Proportion of BAFF-R+ B cells (CD19+ BAFF-R+), IL-17 secreting B cells (CD19+ IL-17+), plasma cells (B220− CD138+), and GC B cells (B220+ GL-7+) after curcumin treatment. *P < 0.05 and **P < 0.01

Full size image

Discussion

RA is a systemic autoimmune and inflammatory disease in which immune cells attack healthy cells and tissues [34]. Although RA does not affect survival, patients have painful swelling and joint destruction, which severely compromise their quality of life [35]. The risk factors for RA include age, sex, genetic factors, smoking, and obesity, but immune system dysfunction plays a major role [36,37,38]. Many RA studies have focused on T cells whereas relatively few similar studies have focused on B cells [39]. In a previous study, we showed that SMILE expression inhibits inflammatory bowel disease (IBD) in a mouse model of colitis via the regulation of Foxp3 expression [7]. In this study, we showed that autoimmune pathology in mouse models of RA (CIA and CAIA) was alleviated by the regulation of B cell activation through SMILE overexpression.

To investigate SMILE expression in RA patients, we searched public mRNA sequencing data and found that CREBZF expression was significantly reduced in our 10 RA patients compared to the levels in 10 healthy controls. This result suggested that the expression of SMILE, which is encoded by CREBZF [40], plays a critical role in RA development and immune cell changes.

We therefore investigated the therapeutic potential of SMILE in RA patients in an animal model by injecting CIA mice with a SMILE overexpression vector. In those mice, both the pathology score and the incidence of arthritis were reduced, consistent with the decrease in joint tissue damage. Immunohistochemistry in mouse joint tissues was then performed to identify the signaling pathways by which SMILE suppresses RA development. In a previous study we showed that SMILE expression leads to the upregulation of p-AMPK in mouse models of IBD and experimental autoimmune arthritis [7, 41]. SMILE overexpression was also shown to increase p-AMPK while decreasing mTOR and p-STAT3 expression. mTOR regulates the expression of genes that mediate inflammation, including NF-kB and STAT3 whereas AMPK is an upstream negative regulator of mTOR. BAFF-R levels were also elevated in SMILE-overexpressing mice. BAFF is secreted by macrophage or dendritic cells and plays a critical role in activating B cells by enhancing the levels of autoantibody-producing plasma cells and IL-6-producing effector B cells. BAFF also suppresses IL-10-secreting regulatory B cells. Taken together, this study demonstrated that SMILE expression has a regulatory effect on RA through the regulation of AMPK/mTOR signaling and BAFF expression.

The immunofluorescence images of mouse spleen tissues showed that the overexpression of SMILE notably decreased Th17 cells and increased Treg cells while reducing the number of plasma B cells. These data suggested SMILE-mediated changes in AMPK/mTOR signaling and BAFF expression leading to the regulation of immune cells in vivo. Although the change was not significant, SMILE overexpression decreased the levels of FOB cells and mature B cells and increased the levels of MZB cells, immature B cells, and regulatory B cells (CD5+ CD1Dhigh cells). These results demonstrate that the regulation of AMPK/mTOR and BAFF by SMILE modifies pro-inflammatory immune cells in vivo.

To verify the effect of SMILE, CAIA was induced in SMILE-overexpressing Tg mice. SMILE overexpression suppressed the tissue damage associated with CAIA and decreased collagen antibody production in tissues and blood. The immunofluorescence images indicated that the modifications in AMPK/mTOR and STAT3 induced by SMILE decreased the activation of B cells.

Curcumin, a member of the ginger family, is produced by plants of the Curcuma longa species [42, 43]. It is generally recognized as safe for its intended use by the U.S. Food and Drug Administration [44]. However, curcumin may also have therapeutic applications in numerous diseases [45]. Our previous studies showed an immune regulatory effect of curcumin in mouse models of autoimmune disease, although our focus was on T cell function [46, 47]. In other studies, curcumin has been shown to increase SMILE expression and regulate endoplasmic reticulum stress [32, 33]. Hence, in this study curcumin was used as a SMILE inducer. Curcumin was shown to elevate SMILE transcription by about fivefold, reduce B cell activation, and decrease the levels of plasma B cells, GC B cells, IL-17-secreting CD19+ B cells, and BAFF-R-expressing B cells in this data.

Despite the many studies of RA and its treatment, its pathogenesis has yet to be elucidated and there is no complete cure. In this study, we present the first evidence that SMILE can be used as a therapeutic agent for RA, based on its ability to inhibit B cell activation by regulating the AMPK/mTOR signaling pathway and BAFF expression.

Availability of data and materials

Requests to access the datasets should be directed to Mi-La Cho, iammila@catholic.ac.kr.

References

  1. Hu Z, Han Y, Liu Y, Zhao Z, Ma F, Cui A, Zhang F, Liu Z, Xue Y, Bai J, et al. CREBZF as a key regulator of STAT3 pathway in the control of liver regeneration in mice. Hepatology. 2020;71:1421–36.

    Article  CAS  PubMed  Google Scholar 

  2. Lopez-Mateo I, Villaronga MA, Llanos S, Belandia B. The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle. 2012;11:3887–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lu M, Zhang R, Yu T, Wang L, Liu S, Cai R, Guo X, Jia Y, Wang A, Jin Y, Lin P. CREBZF regulates testosterone production in mouse Leydig cells. J Cell Physiol. 2019;234:22819–32.

    Article  CAS  PubMed  Google Scholar 

  4. Zhang F, Hu Z, Li G, Huo S, Ma F, Cui A, Xue Y, Han Y, Gong Q, Gao J, et al. Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in diet-induced insulin-resistant mice. Hepatology. 2018;68:1361–75.

    Article  CAS  PubMed  Google Scholar 

  5. Wang W, Xu RL, He P, Chen R. MAR1 suppresses inflammatory response in LPS-induced RAW 264.7 macrophages and human primary peripheral blood mononuclear cells via the SIRT1/PGC-1alpha/PPAR-gamma pathway. J Inflamm (Lond). 2021;18:8.

    Article  PubMed  Google Scholar 

  6. Lee JM, Han HS, Jung YS, Harris RA, Koo SH, Choi HS. The SMILE transcriptional corepressor inhibits cAMP response element-binding protein (CREB)-mediated transactivation of gluconeogenic genes. J Biol Chem. 2018;293:13125–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yang S, Park JS, Hwang SH, Cho KH, Na HS, Choi J, Jhun J, Kim SJ, Lee BI, Park SH, Cho ML. Metformin-inducible small heterodimer partner interacting leucine zipper protein ameliorates intestinal inflammation. Front Immunol. 2021;12: 652709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Degboe Y, Rauwel B, Baron M, Boyer JF, Ruyssen-Witrand A, Constantin A, Davignon JL. Polarization of rheumatoid macrophages by TNF targeting through an IL-10/STAT3 mechanism. Front Immunol. 2019;10:3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017;46:183–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8:656–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Jiang Q, Yang G, Liu Q, Wang S, Cui D. Function and role of regulatory T cells in rheumatoid arthritis. Front Immunol. 2021;12: 626193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kondo Y, Yokosawa M, Kaneko S, Furuyama K, Segawa S, Tsuboi H, Matsumoto I, Sumida T. Review: transcriptional regulation of CD4+ T cell differentiation in experimentally induced arthritis and rheumatoid arthritis. Arthritis Rheumatol. 2018;70:653–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021;22:10–8.

    Article  CAS  PubMed  Google Scholar 

  15. Lubberts E. Th17 cytokines and arthritis. Semin Immunopathol. 2010;32:43–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Noack M, Miossec P. Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol. 2017;39:365–83.

    Article  CAS  PubMed  Google Scholar 

  17. Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun. 2018;87:1–15.

    Article  CAS  PubMed  Google Scholar 

  18. Talotta R, Berzi A, Atzeni F, Batticciotto A, Clerici M, Sarzi-Puttini P, Trabattoni D. Paradoxical expansion of Th1 and Th17 lymphocytes in rheumatoid arthritis following infliximab treatment: a possible explanation for a lack of clinical response. J Clin Immunol. 2015;35:550–7.

    Article  CAS  PubMed  Google Scholar 

  19. Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2010;22:307–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rivellese F, Pontarini E, Pitzalis C. Tertiary lymphoid organs in rheumatoid arthritis. Curr Top Microbiol Immunol. 2020;426:119–41.

    CAS  PubMed  Google Scholar 

  21. Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, Zhang L. B cells in rheumatoid arthritispathogenic mechanisms and treatment prospects. Front Immunol. 2021;12: 750753.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Demoor T, Bracke KR, Maes T, Vandooren B, Elewaut D, Pilette C, Joos GF, Brusselle GG. Role of lymphotoxin-alpha in cigarette smoke-induced inflammation and lymphoid neogenesis. Eur Respir J. 2009;34:405–16.

    Article  CAS  PubMed  Google Scholar 

  23. Elemam NM, Hannawi S, Maghazachi AA. Role of chemokines and chemokine receptors in rheumatoid arthritis. Immunotargets Ther. 2020;9:43–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Lalor SJ, Segal BM. Lymphoid chemokines in the CNS. J Neuroimmunol. 2010;224:56–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Pan Z, Zhu T, Liu Y, Zhang N. Role of the CXCL13/CXCR5 axis in autoimmune diseases. Front Immunol. 2022;13: 850998.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kristyanto H, Blomberg NJ, Slot LM, van der Voort EIH, Kerkman PF, Bakker A, Burgers LE, Ten Brinck RM, van der Helm-van Mil AHM, Spits H, et al. Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis. Sci Transl Med. 2020;12:eaaz5327.

    Article  CAS  PubMed  Google Scholar 

  27. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med. 2005;201:1659–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Liu J, Gao J, Wu Z, Mi L, Li N, Wang Y, Peng X, Xu K, Wu F, Zhang L. Anti-citrullinated protein antibody generation, pathogenesis, clinical application, and prospects. Front Med. 2021;8: 802934.

    Article  Google Scholar 

  29. Moore AR, Allden S, Bourne T, Denis MC, Kranidioti K, Okoye R, Sotsios Y, Stencel Z, Vugler A, Watt G, Shaw S. Collagen II antibody-induced arthritis in Tg1278TNFko mice: optimization of a novel model to assess treatments targeting human TNFalpha in rheumatoid arthritis. J Transl Med. 2014;12:285.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Jhun J, Min HK, Ryu J, Lee SY, Ryu JG, Choi JW, Na HS, Lee SY, Jung Y, Park SJ, et al. Lactobacillus sakei suppresses collagen-induced arthritis and modulates the differentiation of T helper 17 cells and regulatory B cells. J Transl Med. 2020;18:317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gunarta IK, Yuliana D, Erdenebaatar P, Kishi Y, Boldbaatar J, Suzuki R, Odongoo R, Davaakhuu G, Hohjoh H, Yoshioka K. c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 (JSAP1) attenuates curcumin-induced cell death differently from its family member, JNK-associated leucine zipper protein (JLP). Drug Discov Ther. 2021;15:66–72.

    Article  CAS  PubMed  Google Scholar 

  32. Misra J, Chanda D, Kim DK, Li T, Koo SH, Back SH, Chiang JYL, Choi HS. Curcumin differentially regulates endoplasmic reticulum stress through transcriptional corepressor SMILE (small heterodimer partner-interacting leucine zipper protein)-mediated inhibition of CREBH (cAMP responsive element-binding protein H). J Biol Chem. 2011;286:41972–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Son HE, Kim EJ, Jang WG. Curcumin induces osteoblast differentiation through mild-endoplasmic reticulum stress-mediated such as BMP2 on osteoblast cells. Life Sci. 2018;193:34–9.

    Article  CAS  PubMed  Google Scholar 

  34. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–38.

    Article  CAS  PubMed  Google Scholar 

  35. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.

    Article  PubMed  Google Scholar 

  36. Derksen V, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol. 2017;39:437–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Scherer HU, Haupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020;110: 102400.

    Article  CAS  PubMed  Google Scholar 

  38. Weyand CM, Fujii H, Shao L, Goronzy JJ. Rejuvenating the immune system in rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:583–8.

    Article  CAS  PubMed  Google Scholar 

  39. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20:179–99.

    Article  CAS  PubMed  Google Scholar 

  40. Chen F, Lin PF, Li X, Sun J, Zhang Z, Du E, Wang A, Jin YP. Construction and expression of lentiviral vectors encoding recombinant mouse CREBZF in NIH 3T3 cells. Plasmid. 2014;76:24–31.

    Article  CAS  PubMed  Google Scholar 

  41. Lee EJ, Kwon JE, Park MJ, Jung KA, Kim DS, Kim EK, Lee SH, Choi JY, Park SH, Cho ML. Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE. Immunol Lett. 2017;188:1–8.

    Article  CAS  PubMed  Google Scholar 

  42. Noureddin SA, El-Shishtawy RM, Al-Footy KO. Curcumin analogues and their hybrid molecules as multifunctional drugs. Eur J Med Chem. 2019;182: 111631.

    Article  CAS  PubMed  Google Scholar 

  43. Rodrigues FC, Kumar NA, Thakur G. The potency of heterocyclic curcumin analogues: an evidence-based review. Pharmacol Res. 2021;166: 105489.

    Article  CAS  PubMed  Google Scholar 

  44. Stati G, Rossi F, Sancilio S, Basile M, Di Pietro R. Curcuma longa hepatotoxicity: A baseless accusation. Cases assessed for causality using RUCAM method. Front Pharmacol. 2021;12:780330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174:1325–48.

    Article  CAS  PubMed  Google Scholar 

  46. Jhun J, Min HK, Na HS, Kwon JY, Ryu J, Cho KH, Choi J, Jung K, Lee SY, Kim SJ, et al. Combinatmarion treatment with Lactobacillus acidophilus LA-1, vitamin B, and curcumin ameliorates the progression of osteoarthritis by inhibiting the pro-inflammatory mediators. Immunol Lett. 2020;228:112–21.

    Article  CAS  PubMed  Google Scholar 

  47. Park MJ, Moon SJ, Lee SH, Yang EJ, Min JK, Cho SG, Yang CW, Park SH, Kim HY, Cho ML. Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells. PLoS ONE. 2013;8: e67171.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1F1A1056064), Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (Grant Number 2020R1I1A1A01072520) and the Institute of Clinical Medicine Research of Bucheon St. Mary’s Hospital, Research Fund (grant number BCMC20AC04).

Author information

Author notes

  1. JooYeon Jhun and Jeonghyeon Moon contributed equally to this work

Authors and Affiliations

  1. Rheumatism Research Center, College of Medicine, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, 06591, Korea

    JooYeon Jhun, Ji Ye Kwon, Keun-Hyung Cho, Seang Yoon Lee, Hyun Sik Na & Mi-La Cho

  2. Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, 06591, Korea

    JooYeon Jhun, Keun-Hyung Cho, Seang Yoon Lee, Hyun Sik Na & Mi-La Cho

  3. Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, 222, Banpo-Daero, Seocho-gu, Seoul, 06591, Republic of Korea

    JooYeon Jhun, Keun-Hyung Cho, Seang Yoon Lee & Hyun Sik Na

  4. Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, 06511, CT, USA

    Jeonghyeon Moon

  5. Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea

    Mi-La Cho

  6. Department of Internal Medicine, The Clinical Medicine Research Institute of Bucheon St. Mary’s Hospital, Bucheon-si, South Korea

    Jun-Ki Min

Authors
  1. JooYeon Jhun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeonghyeon Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ji Ye Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Keun-Hyung Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seang Yoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hyun Sik Na
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mi-La Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun-Ki Min
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JJ, JM, MLC and JKM designed the experiments and interpreted the data. JJ and JM wrote the original draft of manuscript. The data of in vitro and in vivo experiments were performed by JJ, JM, JYK, SL and HSN. KHC conducted H&E, Safranin O staining and immunohistochemistry experiments. All authors critically reviewed and approved the final form of the manuscript.

Corresponding authors

Correspondence to Mi-La Cho or Jun-Ki Min.

Ethics declarations

Ethics approval and consent to participate

The study protocol involving human participants was approved by the Institutional Review Board of Seoul St. Mary’s Hospital. All patients/participants provided written informed consent to participate in this study. The animal study protocol was approved by the Animal Research Ethics Committee of the Catholic University of Korea.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jhun, J., Moon, J., Kwon, J.Y. et al. Small heterodimer partner interacting leucine zipper protein (SMILE) ameliorates autoimmune arthritis via AMPK signaling pathway and the regulation of B cell activation. Cell Commun Signal 21, 98 (2023). https://doi.org/10.1186/s12964-023-01054-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12964-023-01054-y

Keywords

Cell Communication and Signaling

ISSN: 1478-811X